{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:55:45Z","timestamp":1780602945251,"version":"3.54.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Environ Sci Pollut Res"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11356-021-18035-8","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:04:35Z","timestamp":1642205075000},"page":"18302-18304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Letter to the editor on Ghitani SA et al. Outbreak of foodborne botulism in Alexandria, Egypt. Modulating indications for administration of heptavalent botulinum antitoxin DOI: 10.1007\/s11356-021\u201314909-z"],"prefix":"10.1007","volume":"29","author":[{"given":"Ling","family":"Claytor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"18035_CR1","unstructured":"BAT\u00ae (2020) [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] Sterile solution for injection [package insert]. Emergent BioSolutions Canada Inc., Winnipeg"},{"key":"18035_CR2","first-page":"326","volume-title":"Current therapy in equine medicine","author":"WV Bernard","year":"1997","unstructured":"Bernard WV (1997) Botulism. In: Robinson NR (ed) Current therapy in equine medicine, 4th edn. WB Saunders Co, Philadelphia, pp 326\u2013328","edition":"4"},{"key":"18035_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-14909-z","author":"SA Ghitani","year":"2021","unstructured":"Ghitani SA, Ghanem MA, Sultan EA, Atef M, Henaidy MF (2021) Outbreak of foodborne botulism in Alexandria, Egypt: modulating indications for administration of heptavalent botulinum antitoxin. Environ Sci Pollut Res Int. https:\/\/doi.org\/10.1007\/s11356-021-14909-z (online ahead of print)","journal-title":"Environ Sci Pollut Res Int"},{"issue":"No. RR-2","key":"18035_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7002a1","volume":"70","author":"AK Rao","year":"2021","unstructured":"Rao AK, Sobel J, Chatham-Stephens K, Luquez C (2021) Clinical guidelines for diagnosis and treatment of botulism. MMWR Recomm Rep 70(No. RR-2):1\u201330. https:\/\/doi.org\/10.15585\/mmwr.rr7002a1","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"18035_CR5","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/cid\/ciz515","volume":"70","author":"JS Richardson","year":"2020","unstructured":"Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T (2020) Safety and clinical outcomes of an equine-derived heptavalent botulinum antitoxin treatment for confirmed or suspected botulism in the United States. Clin Infect Dis 70(9):1950\u20131957. https:\/\/doi.org\/10.1093\/cid\/ciz515","journal-title":"Clin Infect Dis"},{"issue":"S1","key":"18035_CR6","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/cid\/cix816","volume":"66","author":"PA Yu","year":"2018","unstructured":"Yu PA, Lin NH, Mahon BE, Sobel J, Yu Y, Mody RK, Gu W, Clements J, Kim H, Rao AK (2018) Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin. Clin Infect Dis 66(S1):S57-64. https:\/\/doi.org\/10.1093\/cid\/cix816","journal-title":"Clin Infect Dis"}],"container-title":["Environmental Science and Pollution Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-18035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11356-021-18035-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11356-021-18035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T05:39:53Z","timestamp":1645767593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11356-021-18035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":6,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["18035"],"URL":"https:\/\/doi.org\/10.1007\/s11356-021-18035-8","relation":{},"ISSN":["0944-1344","1614-7499"],"issn-type":[{"value":"0944-1344","type":"print"},{"value":"1614-7499","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of this writing, Ling Claytor is an active employee of Emergent BioSolutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}